Jaypirca EU approval recommendation for leukemia lifts Eli Lilly stock above $1,184

Traders Union
All News
Financial News
Eli Lilly surges 5.08% after EU win

Highlights

Eli Lilly's Jaypirca won positive recommendation from the European Medicines Agency for chronic lymphocytic leukemia across all treatment lines, expanding market potential in Europe.
Pipeline and geographic growth momentum is reinforced by Lilly's Centessa Pharmaceuticals acquisition, Jaypirca's launch in India, and a $9.2 million ProQR investment.
LLY maintains a strongly bullish technical structure with aggressive buying, forecasting consolidation between $1,155 and $1,214, with low downside risk but overbought indicators suggesting short-term pullback potential.

Oncology breakthrough and deal activity drive expansion prospects

Eli Lilly has secured a major regulatory milestone, as the European Medicines Agency's Committee for Medicinal Products for Human Use recommended Jaypirca (pirtobrutinib) for approval as a treatment for adults with chronic lymphocytic leukemia across all lines of therapy, according to Prnewswire. This development meaningfully broadens Lilly’s reach in the European oncology market and unlocks new commercial opportunities on the continent, providing a clear catalyst for demand. Additional momentum is supported by the completed acquisition of Centessa Pharmaceuticals, which adds clinical-stage sleep disorder assets to the pipeline as reported by Pulse2, the commercial launch of Tanstrive (selpercatinib) in India following marketing authorization according to Business Standard, and a $9.2 million investment in ProQR Therapeutics to maintain its ownership stake, per Benzinga.

Overbought signals persist as support strengthens near key averages

LLY trades above the hourly MA-20 at $1,125 and MA-50 at $1,115, and remains well above the daily MA-200 at $973. The Ichimoku Kijun level on the daily chart provides immediate support at $1,139. On the momentum side, both the Moving Average Convergence Divergence (MACD) and the Average Directional Index (ADX) are at Buy, while the Relative Strength Index (RSI) prints at 79.77, and both the Commodity Channel Index (CCI) and Stochastic RSI are in overbought territory. Bull/Bear Power is also overbought, indicating strong session-long buyer dominance, with the Awesome Oscillator confirming the prevailing uptrend.

Upside breakout odds rise as consolidation range narrows

Over the next 2 to 3 trading days, LLY is expected to consolidate within a typical volatility band between $1,155 and $1,214. The probability of an upside breakout remains very high, while the odds of a downside scenario are low. A sustained move above $1,214 could trigger further gains, while a drop below the Ichimoku Kijun support at $1,139 might prompt a pullback beneath the projected range.

Viktoras Karapetjanc, expert at Traders Union, sees Eli Lilly’s fundamental and macro backdrop as highly supportive. He believes the EMA recommendation for Jaypirca unlocks material new market potential in Europe. The analyst notes recent acquisitions and product launches further diversify and strengthen Lilly’s pipeline. Near-term sentiment and technicals remain constructive, with clear upside catalysts in place. "Momentum is backed by regulatory progress and expansion strategies, so I expect bullish continuation in LLY above $1,155 as long as support holds," says Karapetjanc.

Earlier, analysts noted that Eli Lilly's expanding oncology pipeline and strategic acquisitions had positioned the company favorably for continued growth and strong momentum. With the latest regulatory advance for Jaypirca in Europe and evident buyer dominance, traders should closely monitor price action for a potential breakout above $1,214 as bullish catalysts accumulate.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.